九月婷婷综合婷婷_碰碰视频免费_人人做人人澡人人人爽_亚洲日韩中文在线

賽培新增產(chǎn)品文章：人TNF-α、 IL-6、MMP-2、MMP-9 和 SDF-1 ELISA試劑盒

發(fā)布時間：2022-09-16 16:37:55

左卡尼汀聯(lián)合金水寶治療維持性血液透析 慢性腎功能衰竭患者的臨床效果觀察
何雪1，殷芳2 ( 重慶醫(yī)科大學(xué)附屬永川醫(yī)院 1． 腎病風(fēng)濕科，2． 感染科，重慶 402160) ［摘要］ 目的: 觀察左卡尼汀聯(lián)合金水寶治療維持性血液透析慢性腎功能衰竭患者的臨床效果。方法: 選擇 2018 年 6 月至 2021 年 2 月在重慶醫(yī)科大學(xué)附屬永川醫(yī)院行維持性血液透析的慢性腎功能衰竭患者 92 例，隨機(jī)分 為治療組( n = 46) 和對照組( n = 46) 。對照組采用左卡尼汀治療，治療組在對照組基礎(chǔ)上聯(lián)合金水寶治療。比較 兩組臨床療效以及血清中炎癥因子、基質(zhì)金屬蛋白酶( MMP) 、營養(yǎng)指標(biāo)、基質(zhì)細(xì)胞衍生因子-1( SDF-1) 、維生素 D 及維生素 B12 水平。結(jié)果: 治療后，治療組臨床總有效率( 89． 13% ) 顯著高于對照組( 69． 57% ，P ＜ 0． 05) 。治療 后，兩組腫瘤壞死因子-α( TNF-α) 、IL-6、C 反應(yīng)蛋白( CＲP) 、MMP-2、MMP-9、SDF-1 水平較治療前明顯降低( P 均 ＜ 0． 05) ，總蛋白、白蛋白、血紅蛋白、維生素 D、維生素 B12 水平較治療前明顯升高( P 均 ＜ 0． 05) ; 且治療組 TNF-α、 IL-6、CＲP、MMP-2、MMP-9、SDF-1 水平明顯低于對照組( P 均 ＜ 0． 05) ，總蛋白、白蛋白、血紅蛋白、維生素 D、維生素 B12 水平明顯高于對照組( P 均 ＜ 0． 05) 。兩組不良反應(yīng)、并發(fā)癥發(fā)生率比較，差異無統(tǒng)計學(xué)意義( P 均 ＞ 0． 05) 。結(jié) 論: 左卡尼汀聯(lián)合金水寶治療可提高維持性血液透析慢性腎功能衰竭患者臨床效果，減輕微炎癥反應(yīng)，改善營養(yǎng)狀 態(tài)。 ［關(guān)鍵詞］ 左卡尼汀; 金水寶; 慢性腎功能衰竭; 維持性血液透析; 基質(zhì)金屬蛋白酶; 基質(zhì)細(xì)胞衍生因子-1; 維生素 D; 維生素 B12 ［中圖分類號］ Ｒ459． 5; Ｒ692． 5 ［文獻(xiàn)標(biāo)志碼］ A ［文章編號］ 1671 － 7783( 2022) 02 － 0156 － 05 DOI: 10． 13312 /j． issn． 1671-7783． y210117 ［引用格式］何雪，殷芳． 左卡尼汀聯(lián)合金水寶治療維持性血液透析慢性腎功能衰竭患者的臨床效果觀察［J］． 江 蘇大學(xué)學(xué)報( 醫(yī)學(xué)版) ，2022，32( 2) : 156 － 160，166． ［基金項目］重慶市教育委員會項目( KJQN201900420) ［作者簡介］何雪( 1990—) ，女，碩士研究生，住院醫(yī)師; 殷芳( 通訊作者) ，E-mail: Ahappy2021@ 126． com
Clinical efficacy of levocarnitine combined with Jinshuibao in the treatment of patients with chronic renal failure undergoing maintenance hemodialysis
  HE Xue1，YIN Fang2 ( 1． Department of Nephrology and Ｒheumatology，2． Department of Infection，Yongchuan Hospital Affiliated to Chongqing Medical University，Chongqing 402160，China) ［Abstract］ Objective: To evaluate the clinical effect of levocarnitine combined with Jinshuibao on patients with chronic renal failure patients undergoing maintenance hemodialysis． Methods: Ninety-two patients with chronic renal failure who underwent maintenance hemodialysis in Yongchuan Hospital Affiliated to Chongqing Medical University from June 2018 to February 2021 were selected in the study， and were randomly divided into the treatment group ( n = 46) and the control group ( n = 46) ． The control group was treated with levocarnitine，and the treatment group was treated with Jinshuibao on the basis of the control group． Clinical efficacy and level of inflammatory factors，matrix metalloproteinases， nutritional indicators，stromal cell-derived factor-1 ( SDF-1) ，vitamin D and vitamin B12 in serum were compared between the two groups． Ｒesults: After treatment，the total clinical effective rate of treatment group ( 89． 13% ) was significantly higher than that of control group ( 69． 57% ，P ＜ 0． 05 ) ． After treatment，the levels of tumor necrosis factor-α ( TNF-α) ，IL-6，C-reactive protein ( CＲP) ，matrixmetalloproteinase-2 ( MMP-2 ) ，matrix metalloproteinase-9 ( MMP-9 ) and SDF-1 in 2 groups were significantly decreased compared with before treatment ( all P ＜ 0． 05 ) ． The levels of total protein， albumin，hemoglobin，vitamin D and vitamin B12 were higher than those before treatment ( all P ＜ 0． 05) ; and the contents of TNF-α，IL-6，CＲP，MMP-2，MMP-9 and SDF-1 in treatment group were lower than those in control group ( P ＜ 0． 05) ，and the levels of total protein，albumin，hemoglobin， vitamin D and vitamin B12 in treatment group were higher than those in control group( P ＜ 0． 05) ． There was no significant difference in the incidence of adverse reactions and complication between the two groups( both P ＞ 0． 05) ． Conclusion: Levocarnitine combined with Jinshuibao could improve the clinical efficacy，reduce micro-inflammatory reaction，improve nutritional status in patients with chronic renal failure undergoing maintenance hemodialysis． ［Key words］ levocarnitine; Jinshuibao; chronic renal failure; maintenance hemodialysis; matrix metalloproteinase; stromal cell derived factor-1; Vitamin D; Vitamin B12


左卡尼汀聯(lián)合金水寶治療維持...功能衰竭患者的臨床效果觀察_何雪.pdf